1
|
Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, Samuel VP, Gubbiyappa SK, Subramaniyan V. MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting. Pathol Res Pract 2024; 253:154991. [PMID: 38070223 DOI: 10.1016/j.prp.2023.154991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Revised: 11/21/2023] [Accepted: 11/27/2023] [Indexed: 01/24/2024]
Abstract
Lung cancer remains a formidable global health burden, necessitating a comprehensive understanding of the underlying molecular mechanisms driving its progression. Recently, lncRNAs have become necessary controllers of various biological functions, including cancer development. MALAT1 has garnered significant attention due to its multifaceted role in lung cancer progression. Lung cancer, among other malignancies, upregulates MALAT1. Its overexpression has been associated with aggressive tumor behavior and poor patient prognosis. MALAT1 promotes cellular proliferation, epithelial-mesenchymal transition (EMT), and angiogenesis in lung cancer, collectively facilitating tumor growth and metastasis. Additionally, MALAT1 enhances cancer cell invasion by interacting with numerous signaling pathways. Furthermore, MALAT1 has been implicated in mediating drug resistance in lung cancer, contributing to the limited efficacy of conventional therapies. Recent advancements in molecular biology and high-throughput sequencing technologies have offered fresh perspectives into the regulatory networks of MALAT1 in lung cancer. It exerts its oncogenic effects by acting as a ceRNA to sponge microRNAs, thereby relieving their inhibitory effects on target genes. Moreover, MALAT1 also influences chromatin remodeling and post-translational modifications to modulate gene expression, further expanding its regulatory capabilities. This review sheds light on the multifaceted roles of MALAT1 in lung cancer progression, underscoring its potential as an innovative therapeutic target and diagnostic biomarker. Targeting MALAT1 alone or combined with existing therapies holds promise to mitigate lung cancer progression and improve patient outcomes.
Collapse
Affiliation(s)
- Asif Ahmad Bhat
- School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur 302017, India
| | - Obaid Afzal
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia
| | - Muhammad Afzal
- Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi Arabia
| | - Gaurav Gupta
- Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India; School of Pharmacy, Graphic Era Hill University, Dehradun 248007, India
| | - Riya Thapa
- School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur 302017, India
| | - Haider Ali
- Department of Pharmacology, Kyrgyz State Medical College, Bishkek, Kyrgyzstan
| | - Waleed Hassan Almalki
- Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
| | - Imran Kazmi
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
| | - Sami I Alzarea
- Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Al-Jouf, Saudi Arabia
| | - Shakir Saleem
- Department of Public Health. College of Health Sciences, Saudi Electronic University, Riyadh, Saudi Arabia
| | - Vijaya Paul Samuel
- Department of Anatomy, RAK College of Medicine, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE
| | | | - Vetriselvan Subramaniyan
- Pharmacology Unit, Jeffrey Cheah School of Medicine and Health Sciences, Monash University, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia
| |
Collapse
|
2
|
Wu Y, Sreeharsha N, Sharma S, Mishra A, Singh AK, Gubbiyappa SK. Retraction of "Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis". ACS Omega 2021; 6:33239. [PMID: 34901676 PMCID: PMC8656203 DOI: 10.1021/acsomega.1c06159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Indexed: 06/14/2023]
Abstract
[This retracts the article DOI: 10.1021/acsomega.9b04357.].
Collapse
|
3
|
Wu Y, Sreeharsha N, Sharma S, Mishra A, Singh AK, Gubbiyappa SK. Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis. ACS Omega 2020; 5:5334-5339. [PMID: 32201822 PMCID: PMC7081392 DOI: 10.1021/acsomega.9b04357] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 02/18/2020] [Indexed: 05/09/2023]
Abstract
Multiple effects on cancer cells are exerted by the peroxisome proliferator-activated receptor γ (PPAR-γ). Recent studies have shown that rosiglitazone, a synthetic PPAR-γ ligand, inhibits the growth of cells. This research was designed to assess the impact of rosiglitazone on diethylnitrosamine (DENA)-induced lung carcinogenesis in Wistar rats and to study the underlying molecular mechanism. A total of 40 adult male Wistar rats were separated into four groups as follows: group 1 is known as a control. Group 2 is known as the DENA group (150 mg/kg, i.p.). Group 3 and group 4 denote DENA-induced rats treated with 5 and 10 mg/kg rosiglitazone, respectively. Lipid peroxidation, various antioxidant enzymes, histological perceptions, and caspase-3, Bcl2, and Bax gene expression were measured in lung tissues. Rosiglitazone treatment reverted the DENA-induced changes in the expression of these genes, inflammatory cytokines, and oxidative stress. However, blotting analysis discovered reduced caspase-3 and BAX expressions and elevated Bcl-2 expression in DENA-induced rats. The expression of such proteins causing DENA lung cancer was restored by rosiglitazone therapy.
Collapse
Affiliation(s)
- Yanqiao Wu
- Intensive
Care Unit, People’s Hospital of Ningjin
County, Ningjin County, Shandong province 253400, China
| | - Nagaraja Sreeharsha
- Department
of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia
| | - Sanjay Sharma
- NMIMS, School of Pharmacy and
Technology Management, Shirpur 425405, Maharashtra, India
| | - Anurag Mishra
- School
of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India
- E-mail: ,
| | - Avinash Kumar Singh
- Department
of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
| | | |
Collapse
|
4
|
Singh Y, Samuel VP, Dahiya S, Gupta G, Gillhotra R, Mishra A, Singh M, SreeHarsha N, Gubbiyappa SK, Tambuwala MM, Chellappan DK, Dua K. Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia‐associated hypertension. Biotechnol Appl Biochem 2019; 66:715-719. [DOI: 10.1002/bab.1799] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Accepted: 05/18/2019] [Indexed: 12/14/2022]
Affiliation(s)
- Yogendra Singh
- Department of Pharmaceutical Sciences Mahatma Gandhi College of Pharmaceutical Sciences Sitapura Jaipur India
| | - Vijaya Paul Samuel
- Department of Anatomy RAK College of Medicine RAK Medical and Health Sciences, University Ras Al Khaimah UAE
| | - Sunita Dahiya
- Department of Pharmaceutical Sciences School of Pharmacy University of Puerto Rico, Medical Sciences Campus San Juan Puerto Rico USA
| | - Gaurav Gupta
- School of Pharmacy Suresh Gyan Vihar University Jagatpura Jaipur India
| | - Ritu Gillhotra
- School of Pharmacy Suresh Gyan Vihar University Jagatpura Jaipur India
| | - Anurag Mishra
- School of Pharmacy Suresh Gyan Vihar University Jagatpura Jaipur India
| | - Mahaveer Singh
- School of Pharmaceutical Sciences Jaipur National University Jagatpura Jaipur India
| | - Nagaraja SreeHarsha
- Department of Pharmaceutical Sciences College of Clinical Pharmacy King Faisal University Al‐Ahsa Saudi Arabia
| | | | - Murtaza M. Tambuwala
- School of Pharmacy & Pharmaceutical Sciences Ulster University Coleraine Northern Ireland UK
| | | | - Kamal Dua
- Discipline of Pharmacy Graduate School of Health University of Technology Sydney Sydney NSW Australia
- Priority Research Centre for Healthy Lungs School of Biomedical Sciences and Pharmacy The University of Newcastle Callaghan Australia
| |
Collapse
|
5
|
Samuel VP, Dahiya R, Singh Y, Gupta G, Sah SK, Gubbiyappa SK, Chellappan DK, Dua K. Metformin: A Salutary Candidate for Colorectal Cancer Treatment in Patients with Diabetes. J Environ Pathol Toxicol Oncol 2019; 38:133-141. [DOI: 10.1615/jenvironpatholtoxicoloncol.2019029388] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|